A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Sponsor

Hoffmann-La Roche (Industry)

Overall Status

Terminated

CT.gov ID

NCT02624986

Collaborator

(none)

Enrollment

Locations

Arms

40.9

Actual Duration (Months)

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R/R FL and rituximab in combination with idasanutlin in R/R DLBCL. The study will include an initial dose-escalation phase followed by an expansion phase. The dose-escalation phase is designed to determine the recommended phase 2 dose (RP2D) for idasanutlin in combination with obinutuzumab for FL and in combination with rituximab for DLBCL. The expansion phase is designed to further assess the safety and efficacy of obinutuzumab in combination with idasanutlin at the RP2D with the selected regimen in participants with R/R FL and of rituximab in combination with idasanutlin at the RP2D in participants with R/R DLBCL.

Condition or Disease	Intervention/Treatment	Phase
Non-Hodgkin's Lymphoma	Drug: Idasanutlin Drug: Obinutuzumab Drug: Rituximab	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

25 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Actual Study Start Date :

Dec 23, 2015

Actual Primary Completion Date :

May 20, 2019

Actual Study Completion Date :

May 20, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Drug: Obinutuzumab Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months. Other Names: RO5072759
Experimental: DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Obinutuzumab Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months. Other Names: RO5072759
Experimental: DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Obinutuzumab Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months. Other Names: RO5072759
Experimental: DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2 Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Rituximab Participants received a fixed dose of rituximab, 375 mg/m^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity. Other Names: RO0452294
Experimental: DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2 Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Rituximab Participants received a fixed dose of rituximab, 375 mg/m^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity. Other Names: RO0452294
Experimental: FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Obinutuzumab Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months. Other Names: RO5072759
Experimental: FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Obinutuzumab Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months. Other Names: RO5072759
Experimental: FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).	Drug: Idasanutlin Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing. Other Names: RO5503781 Drug: Obinutuzumab Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months. Other Names: RO5072759

Outcome Measures

Primary Outcome Measures

Percentage of Participants With Complete Response at the End of Induction, Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scans Using Modified Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The plan was for the IRC to evaluate responses at the end of induction treatment in participants from the expansion phase using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based complete response (CR), which required a complete metabolic response with a score of 1, 2, or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [≤] mediastinum; 3 = uptake greater than [>] mediastinum and ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if indeterminate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders.

Secondary Outcome Measures

Number of Participants With a Dose-Limiting Toxicity [Cycles 1, 2 (1 cycle is 28 days)]
A dose-limiting toxicity (DLT) was defined as at least one of the following events occurring during Cycle 1 (or first 2 cycles in the bridging FL cohort) of treatment and assessed by the investigator as not clearly related to the underlying disease: Any Grade 5 adverse event (AE; severity graded per NCI-CTCAE v4.0) unless due to the underlying malignancy or extraneous causes; AE of any grade that leads to a delay of more than (>)14 days in the start of the next treatment cycle; Grade 3 or 4 non-hematologic AEs (with exceptions); Lab results suggestive of potential drug-induced liver injury (according to Hy's law); Grade 3 or 4 neutropenia in the presence of sustained fever of >38 C (lasting >5 days) or a documented infection; Grade 4 neutropenia or thrombocytopenia lasting >7 days; Grade 3 or 4 thrombocytopenia if associated with Grade ≥3 bleeding; Other toxicities considered clinically relevant and related to study treatment as determined by the investigator and medical monitor.
Percentage of Participants With Complete Response at the End of Induction, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based complete response (CR), which required a complete metabolic response with a score of 1, 2, or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [≤] mediastinum; 3 = uptake greater than [>] mediastinum and ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if indeterminate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.
Percentage of Participants With Complete Response at the End of Induction, Determined by the Investigator on the Basis of PET-CT Scans Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based complete response (CR), which required a complete metabolic response with a score of 1, 2, or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [≤] mediastinum; 3 = uptake greater than [>] mediastinum and ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions; X = new areas of uptake unlikely to be related to lymphoma). The CR criteria for participants with bone marrow involvement at screening required no evidence of FDG-avid disease in the marrow. PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.
Percentage of Participants With Complete Response at the End of Induction, Determined by the IRC on the Basis of CT Scans Alone Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimetres in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders.
Percentage of Participants With Complete Response at the End of Induction, Determined by the Investigator on the Basis of CT Scans Alone Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The investigator evaluated responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimetres in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders.
Percentage of Participants With Objective Response at the End of Induction, Determined by the IRC on the Basis of PET-CT Scans Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The IRC was to evaluate responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.
Percentage of Participants With Objective Response at the End of Induction, Determined by the Investigator on the Basis of PET-CT Scans Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.
Percentage of Participants With Objective Response at the End of Induction, Determined by an IRC on the Basis of CT Scans Alone Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a ≥50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. Participants without a post-baseline tumor assessment were to be considered non-responders.
Percentage of Participants With Objective Response at the End of Induction, Determined by the Investigator on the Basis of CT Scans Alone Using Lugano 2014 Criteria [Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)]
The investigator was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a ≥50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. Participants without a post-baseline tumor assessment were to be considered non-responders.
Percentage of Participants With Best Response of Complete Response or Partial Response During the Study, Determined by the Investigator on the Basis of CT Scans Alone Using Lugano 2014 Criteria [Baseline, Cycle 2, end of induction (up to 6 cycles; 1 cycle is 28 days), every 2 months (FL) until end of maintenance or at 4 months (DLBCL) of consolidation treatment, and then every 6 months during follow-up until disease progression (up to 3.5 years)]
The investigator was to evaluate responses throughout the study using the Lugano 2014 response criteria for malignant lymphoma for a CT-based best response of a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a ≥50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. Participants without a post-baseline tumor assessment were to be considered non-responders.
Plasma Idasanutlin Concentrations in DLBCL and FL Participants at Nominal Sampling Timepoints Grouped by Idasanutlin Dose and Combination Partner (Obinutuzumab or Rituximab) [Predose (0 hours) and 6 hours postdose on Day 1 of Cycles 1, 2, and 4; Predose (0 hours) and 2, 4, 6, and 24 hours postdose on Day 5 of Cycles 1 and 2; Predose (0 hours) and 6 and 24 hours postdose on Cycle 4, Day 5 (1 cycle is 28 days)]
The concentration of idasanutlin was determined using a validated assay. The duplication of the predose timepoint (0 hours) on Day 5 as an additional 24-hour timepoint on Day 5 was done in order to conduct pharmacokinetics analysis via non-compartmental analysis, and to derive idasanutlin exposure estimates up to the 24-hour post Day 5 dosing.
Serum Obinutuzumab Concentrations in DLBCL and FL Participants at Nominal Sampling Timepoints [Pre-infusion (0 hour) and 0.5 hours after end of obinutuzumab infusion on Day 1 of Cycles 1, 2, 4, and 6]
Serum Rituximab Concentrations in DLBCL Participants at Nominal Sampling Timepoints [Pre-infusion (0 hours) at Cycle 1, Day 1 and Cycle 2, Day 1; Post-infusion 0.5 hours at Cycle 1, Day 1 (1 cycle is 28 days)]
Safety Summary of the Number of Participants With at Least One Adverse Event by Type and Severity According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0) [From first dose until 90 days after the last dose of study drug treatment (up to 31 months)]
The adverse event (AE) severity grading scale for the NCI CTCAE v4.0 was used for assessing AE severity. Any AEs that were not specifically listed in the NCI CTCAE, v4.0 were graded per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.
Baseline Value and Change From Baseline Values of Systolic Blood Pressure at Specified Timepoints [Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)]
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Baseline Value and Change From Baseline Values of Diastolic Blood Pressure at Specified Timepoints [Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)]
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Baseline Value and Change From Baseline Values of Pulse Rate at Specified Timepoints [Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)]
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Baseline Value and Change From Baseline Values of Respiratory Rate at Specified Timepoints [Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)]
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Baseline Value and Change From Baseline Values of Body Temperature at Specified Timepoints [Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)]
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Number of Participants by Electrocardiogram (ECG) Results Assessment Shift From Baseline to Specified Post-Baseline Timepoints [Baseline, Induction Cycle 1 Day 1 and Cycle 4 Day 1, End of Induction (up to 6 cycles; 1 cycle is 28 days); Every 2 months during maintenance treatment from Months 1-23; End of Maintenance (up to 24 months); Unscheduled Visits (as clinically indicated)]
Single, resting, 12-lead ECG recordings were to be obtained after the participant had been resting in a supine position for at least 10 minutes. Any morphologic waveform changes or other ECG abnormalities were to be documented and clinical significance was determined based on the presence of symptoms, per the investigator's judgment. If the ECG assessment was missing at baseline then it was recorded as "Missing". The ECG results assessments are presented as the shift from baseline to post-baseline assessments at each timepoint. BL = baseline; Cyc1, D1 = Induction Cycle 1 Day 1; Cyc4, D1 = Induction Cycle 4 Day 1; CS = Clinically Significant; EOI = End of Induction Treatment - Completion/Discontinuation; EOM = End of Maintenance Treatment - Completion/Discontinuation; MM1 = Maintenance Month 1; Unsched = Unscheduled Visit
Hematology Laboratory Test Results Shift Table: Number of Participants by Highest NCI-CTCAE v4.0 Grade at Baseline to Highest Grade Post-Baseline [From Baseline until 35 days after the last dose of study drug (up to 29 months)]
Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest (worst) severity grade (according to NCI-CTCAE v4.0) at baseline to the highest grade post-baseline. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a medical intervention or a change in concomitant therapy. For a patient with multiple post-baseline abnormalities, the highest (worst) grade for a given lab test is reported. Abs. = absolute count; BL = baseline; WBC = white blood cell count
Blood Chemistry Laboratory Test Results Shift Table: Number of Participants by Highest NCI-CTCAE v4.0 Grade at Baseline to Highest Grade Post-Baseline [From Baseline until 35 days after the last dose of study drug (up to 29 months)]
Clinical laboratory tests for blood chemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest (worst) severity grade (according to NCI-CTCAE v4.0) at baseline to the highest grade post-baseline. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a medical intervention or a change in concomitant therapy. For a patient with multiple post-baseline abnormalities, the highest (worst) grade for a given lab test is reported. BL = Baseline; Blood Gluc., Fast. = blood glucose, fasting; SGOT/AST = serum glutamic-oxaloacetic transaminase/aspartate transaminase; SGPT/ALT = serum glutamic-pyruvic transaminase/alanine transaminase; Triacylglyc. Lipase = triacylglycerol lipase

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Histologically documented cluster of differentiation (CD) 20-positive B-cell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an anti-CD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option exists
At least one bidimensionally measurable lesion
Agreement to remain abstinent or use adequate contraception, among women or men of childbearing potential

Exclusion Criteria:

Known CD20-negative status at relapse or progression
Prior allogeneic stem cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1
Current use of systemic corticosteroids greater than (>) 20 mg prednisone per day (or equivalent), or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1
Requirement for chronic anticoagulation
Central nervous system (CNS) disease
Active infection
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Poor hematologic, renal, or hepatic function
Pregnant or lactating women
History of progressive multifocal leukoencephalopathy (PML)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic Arizona	Phoenix	Arizona	United States	85259
2	University of Colorado	Aurora	Colorado	United States	80045
3	Norton Medical Plaza II	Louisville	Kentucky	United States	40207
4	Swedish Cancer Institute	Cary	North Carolina	United States	27513
5	Western Pennsylvania Hospital	Pittsburgh	Pennsylvania	United States	15224
6	Guthrie Clinic	Sayre	Pennsylvania	United States	18840
7	Rhode Island Hospital	Providence	Rhode Island	United States	02903
8	Virginia Commonwealth University	Richmond	Virginia	United States	23298
9	Prince of Wales Hospital	Randwick	New South Wales	Australia	2031
10	Westmead Hospital	Westmead	New South Wales	Australia	2145
11	Linear Clinical Research Limited	Nedlands	Western Australia	Australia	6009
12	Zentralklinikum Augsburg	Augsburg		Germany	86156
13	Charité Research Organisation GmbH Campus-Virchow-Klinikum	Berlin		Germany	13353
14	SLK-Kliniken Heilbronn GmbH	Heilbronn		Germany	74078
15	Universitätsklinikum Köln	Köln		Germany	50937
16	Universitätsklinikum Wurzburg	Würzburg		Germany	97080
17	Keimyung University Dongsan Medical Center	Daegu		Korea, Republic of	41931
18	National Cancer Center	Gyeonggi-do		Korea, Republic of	10408
19	Severance Hospital, Yonsei University Health System	Seoul		Korea, Republic of	03722
20	Asan Medical Center	Seoul		Korea, Republic of	05505
21	Samsung Medical Center	Seoul		Korea, Republic of	06351
22	North Shore Hospital	Auckland		New Zealand	0620
23	Christchurch Hospital	Christchurch		New Zealand	8011
24	Auckland Clinical Studies Limited	Grafton		New Zealand	1010

Sponsors and Collaborators

Hoffmann-La Roche

Investigators

Study Director: Clinical Trials, Hoffmann-La Roche

Study Documents (Full-Text)

Study Protocol and Statistical Analysis Plan - Mar 2, 2017

More Information

Publications

None provided.

Responsible Party:

Hoffmann-La Roche

ClinicalTrials.gov Identifier:

NCT02624986

Other Study ID Numbers:

BH29812
2015-002100-83

First Posted:

Dec 9, 2015

Last Update Posted:

May 18, 2020

Last Verified:

Apr 1, 2020

Studies a U.S. FDA-regulated Drug Product:

Yes

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Lymphoma

Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Rituximab

Obinutuzumab

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail	A total of 45 patients were screened, twenty-five of whom were enrolled in the dose escalation phase. The sponsor decided to terminate the study early and the expansion phase was not opened.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Period Title: Overall Study
STARTED	2	3	2	3	4	2	4	5
Received Any Study Treatment	1	3	2	3	4	2	4	5
COMPLETED	0	0	0	0	0	0	0	0
NOT COMPLETED	2	3	2	3	4	2	4	5

Baseline Characteristics

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	Total
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).	Total of all reporting groups
Overall Participants	2	3	2	3	4	2	4	5	25
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	62.5 (6.4)	70.7 (15.2)	55.5 (10.6)	67.3 (8.4)	56.5 (12.9)	52.5 (6.4)	53.3 (6.7)	64.2 (9.8)	60.6 (10.8)
Sex: Female, Male (Count of Participants)
Female	1 50%	1 33.3%	1 50%	1 33.3%	2 50%	0 0%	2 50%	4 80%	12 48%
Male	1 50%	2 66.7%	1 50%	2 66.7%	2 50%	2 100%	2 50%	1 20%	13 52%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	1 4%
Not Hispanic or Latino	2 100%	3 100%	2 100%	2 66.7%	3 75%	2 100%	4 100%	5 100%	23 92%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	1 4%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	2 100%	0 0%	1 25%	1 50%	2 50%	0 0%	6 24%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
White	2 100%	3 100%	0 0%	2 66.7%	3 75%	1 50%	1 25%	5 100%	17 68%
More than one race	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	1 4%
Unknown or Not Reported	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	1 4%

Outcome Measures

1. Primary Outcome

Title	Percentage of Participants With Complete Response at the End of Induction, Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scans Using Modified Lugano 2014 Criteria
Description	The plan was for the IRC to evaluate responses at the end of induction treatment in participants from the expansion phase using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based complete response (CR), which required a complete metabolic response with a score of 1, 2, or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [≤] mediastinum; 3 = uptake greater than [>] mediastinum and ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if indeterminate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Phase 2), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

2. Secondary Outcome

Title	Number of Participants With a Dose-Limiting Toxicity
Description	A dose-limiting toxicity (DLT) was defined as at least one of the following events occurring during Cycle 1 (or first 2 cycles in the bridging FL cohort) of treatment and assessed by the investigator as not clearly related to the underlying disease: Any Grade 5 adverse event (AE; severity graded per NCI-CTCAE v4.0) unless due to the underlying malignancy or extraneous causes; AE of any grade that leads to a delay of more than (>)14 days in the start of the next treatment cycle; Grade 3 or 4 non-hematologic AEs (with exceptions); Lab results suggestive of potential drug-induced liver injury (according to Hy's law); Grade 3 or 4 neutropenia in the presence of sustained fever of >38 C (lasting >5 days) or a documented infection; Grade 4 neutropenia or thrombocytopenia lasting >7 days; Grade 3 or 4 thrombocytopenia if associated with Grade ≥3 bleeding; Other toxicities considered clinically relevant and related to study treatment as determined by the investigator and medical monitor.
Time Frame	Cycles 1, 2 (1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any study drug.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Any DLT	0 0%	0 0%	2 100%	0 0%	1 25%	0 0%	1 25%	1 20%
Thrombocytopenia	0 0%	0 0%	2 100%	0 0%	1 25%	0 0%	1 25%	1 20%

3. Secondary Outcome

Title	Percentage of Participants With Complete Response at the End of Induction, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria
Description	The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based complete response (CR), which required a complete metabolic response with a score of 1, 2, or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [≤] mediastinum; 3 = uptake greater than [>] mediastinum and ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if indeterminate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
ITT Population: all enrolled participants; exploratory analysis of the dose escalation phase (Phase 1). The study plan was for efficacy analyses to be based on responses in participants enrolled during the expansion phase (Phase 2), but it was not opened (i.e., no enrollment) and the study was terminated early.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	2	3	2	3	4	2	4	5
Number (90% Confidence Interval) [Percentage of participants]	0 0%	33.3 1110%	0 0%	0 0%	0 0%	50.0 2500%	0 0%	40.0 800%

4. Secondary Outcome

Title	Percentage of Participants With Complete Response at the End of Induction, Determined by the Investigator on the Basis of PET-CT Scans Using Lugano 2014 Criteria
Description	The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based complete response (CR), which required a complete metabolic response with a score of 1, 2, or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [≤] mediastinum; 3 = uptake greater than [>] mediastinum and ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions; X = new areas of uptake unlikely to be related to lymphoma). The CR criteria for participants with bone marrow involvement at screening required no evidence of FDG-avid disease in the marrow. PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
ITT Population: all enrolled participants; exploratory analysis of the dose escalation phase (Phase 1). The study plan was for efficacy analyses to be based on responses in participants enrolled during the expansion phase (Phase 2), but it was not opened (i.e., no enrollment) and the study was terminated early.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	2	3	2	3	4	2	4	5
Number (90% Confidence Interval) [Percentage of participants]	0 0%	33.3 1110%	0 0%	0 0%	0 0%	50.0 2500%	0 0%	40.0 800%

5. Secondary Outcome

Title	Percentage of Participants With Complete Response at the End of Induction, Determined by the IRC on the Basis of CT Scans Alone Using Lugano 2014 Criteria
Description	The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimetres in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Phase 2), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

6. Secondary Outcome

Title	Percentage of Participants With Complete Response at the End of Induction, Determined by the Investigator on the Basis of CT Scans Alone Using Lugano 2014 Criteria
Description	The investigator evaluated responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimetres in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
ITT Population: all enrolled participants; exploratory analysis of the dose escalation phase (Phase 1). The study plan was for efficacy analyses to be based on responses in participants enrolled during the expansion phase (Phase 2), but it was not opened (i.e., no enrollment) and the study was terminated early.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	2	3	2	3	4	2	4	5
Number (90% Confidence Interval) [Percentage of participants]	0 0%	33.3 1110%	0 0%	0 0%	0 0%	0 0%	0 0%	20.0 400%

7. Secondary Outcome

Title	Percentage of Participants With Objective Response at the End of Induction, Determined by the IRC on the Basis of PET-CT Scans Using Lugano 2014 Criteria
Description	The IRC was to evaluate responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Phase 2), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

8. Secondary Outcome

Title	Percentage of Participants With Objective Response at the End of Induction, Determined by the Investigator on the Basis of PET-CT Scans Using Lugano 2014 Criteria
Description	The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT-based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
The study plan was for this efficacy analysis to be based on responses in participants enrolled during the expansion phase (Phase 2), but it was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

9. Secondary Outcome

Title	Percentage of Participants With Objective Response at the End of Induction, Determined by an IRC on the Basis of CT Scans Alone Using Lugano 2014 Criteria
Description	The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a ≥50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. Participants without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Phase 2), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

10. Secondary Outcome

Title	Percentage of Participants With Objective Response at the End of Induction, Determined by the Investigator on the Basis of CT Scans Alone Using Lugano 2014 Criteria
Description	The investigator was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a ≥50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. Participants without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks; 1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
The study plan was for this efficacy analysis to be based on responses in participants enrolled during the expansion phase (Phase 2), but it was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

11. Secondary Outcome

Title	Percentage of Participants With Best Response of Complete Response or Partial Response During the Study, Determined by the Investigator on the Basis of CT Scans Alone Using Lugano 2014 Criteria
Description	The investigator was to evaluate responses throughout the study using the Lugano 2014 response criteria for malignant lymphoma for a CT-based best response of a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a ≥50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. Participants without a post-baseline tumor assessment were to be considered non-responders.
Time Frame	Baseline, Cycle 2, end of induction (up to 6 cycles; 1 cycle is 28 days), every 2 months (FL) until end of maintenance or at 4 months (DLBCL) of consolidation treatment, and then every 6 months during follow-up until disease progression (up to 3.5 years)

Outcome Measure Data

Analysis Population Description
The study plan was for this efficacy analysis to be based on responses in participants enrolled during the expansion phase (Phase 2), but it was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Phase 1).

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	0	0	0	0	0	0	0	0

12. Secondary Outcome

Title	Plasma Idasanutlin Concentrations in DLBCL and FL Participants at Nominal Sampling Timepoints Grouped by Idasanutlin Dose and Combination Partner (Obinutuzumab or Rituximab)
Description	The concentration of idasanutlin was determined using a validated assay. The duplication of the predose timepoint (0 hours) on Day 5 as an additional 24-hour timepoint on Day 5 was done in order to conduct pharmacokinetics analysis via non-compartmental analysis, and to derive idasanutlin exposure estimates up to the 24-hour post Day 5 dosing.
Time Frame	Predose (0 hours) and 6 hours postdose on Day 1 of Cycles 1, 2, and 4; Predose (0 hours) and 2, 4, 6, and 24 hours postdose on Day 5 of Cycles 1 and 2; Predose (0 hours) and 6 and 24 hours postdose on Cycle 4, Day 5 (1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
Pharmacokinetics Evaluable Population: all participants who received at least one dose of study drug. For this analysis, FL and DLBCL participants are grouped by idasanutlin dose and combination drug (obinutuzumab or rituximab). The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL/FL Combined: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL/FL Combined: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).
Measure Participants	3	12	2	3	4
Cycle 1, Day 1: 0 hours	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cycle 1, Day 1: 6 hours	1540 (21.6)	2210 (42.4)	5540 (21.5)	2130 (91.3)	2980 (49.9)
Cycle 1, Day 5: 0 hours	1150 (19.9)	2150 (46.4)	4120 (27.3)	1660 (77.9)	2920 (56.8)
Cycle 1, Day 5: 2 hours	1230 (20.8)	3570 (68.4)	7850 (23)	2970 (53.2)	4970 (45.7)
Cycle 1, Day 5: 4 hours	1670 (17.5)	4360 (67.6)	7930 (15.5)	2910 (73.2)	5910 (54.6)
Cycle 1, Day 5: 6 hours	1730 (15.5)	4220 (94.8)	7310 (13.6)	2820 (68.7)	5200 (49.8)
Cycle 1, Day 5: 24 hours	1150 (19.9)	2150 (46.4)	4120 (27.3)	1660 (77.9)	2920 (56.8)
Cycle 2, Day 1: 0 hours	0 (0)	0 (0)	0 (0)
Cycle 2, Day 1: 6 hours	1660 (33.1)	2480 (51.5)	1260 (49.8)
Cycle 2, Day 5: 0 hours	2380 (27.2)	2400 (67)
Cycle 2, Day 5: 2 hours	4050 (54.9)
Cycle 2, Day 5: 4 hours	4200 (38.2)
Cycle 2, Day 5: 6 hours	4010 (31.6)
Cycle 2, Day 5: 24 hours	2380 (27.2)
Cycle 4, Day 1: 0 hours	0 (0)
Cycle 4, Day 1: 6 hours	2730 (9.9)
Cycle 4, Day 5: 0 hours	2600 (25.6)
Cycle 4, Day 5: 6 hours	5210 (19.5)
Cycle 4, Day 5: 24 hours	2600 (25.6)

13. Secondary Outcome

Title	Serum Obinutuzumab Concentrations in DLBCL and FL Participants at Nominal Sampling Timepoints
Description
Time Frame	Pre-infusion (0 hour) and 0.5 hours after end of obinutuzumab infusion on Day 1 of Cycles 1, 2, 4, and 6

Outcome Measure Data

Analysis Population Description
Pharmacokinetics Evaluable Population: all participants who received at least one dose of study drug. This analysis only includes FL and DLBCL participants who received obinutuzumab. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL/FL: Idasanutlin 100/150/200 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma received induction treatment with idasanutlin 100 milligrams (mg), 150 mg, or 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
Measure Participants	17
Cycle 1, Day 1: 0 hours	0 (0)
Cycle 1, Day 1: 0.5 hours	397 (32.9)
Cycle 2, Day 1: 0 hours	325 (59.8)
Cycle 2, Day 1: 0.5 hours	703 (40.2)
Cycle 4, Day 1: 0 hours	346 (46.1)
Cycle 4, Day 1: 0.5 hours	685 (38.5)
Cycle 6, Day 1: 0 hours	303 (49.5)
Cycle 6, Day 1: 0.5 hours	639 (34.2)

14. Secondary Outcome

Title	Serum Rituximab Concentrations in DLBCL Participants at Nominal Sampling Timepoints
Description
Time Frame	Pre-infusion (0 hours) at Cycle 1, Day 1 and Cycle 2, Day 1; Post-infusion 0.5 hours at Cycle 1, Day 1 (1 cycle is 28 days)

Outcome Measure Data

Analysis Population Description
Pharmacokinetics Evaluable Population: all participants who received at least one dose of study drug. This analysis only includes DLBCL participants who received rituximab. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Combined: Idasanutlin 150/200 mg + Rituximab 375 mg/m^2
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) received induction treatment with idasanutlin 150 mg or 200 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).
Measure Participants	7
Cycle 1, Day 1: 0 hours	0 (0)
Cycle 1, Day 1: 0.5 hours	197 (14.1)
Cycle 2, Day 1: 0 hours	37.9 (58.1)

15. Secondary Outcome

Title	Safety Summary of the Number of Participants With at Least One Adverse Event by Type and Severity According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0)
Description	The adverse event (AE) severity grading scale for the NCI CTCAE v4.0 was used for assessing AE severity. Any AEs that were not specifically listed in the NCI CTCAE, v4.0 were graded per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.
Time Frame	From first dose until 90 days after the last dose of study drug treatment (up to 31 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Any Adverse Event (AE)	1 50%	3 100%	2 100%	3 100%	4 100%	2 100%	4 100%	5 100%
Grade 5 AE	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Grade 3-5 AE	1 50%	3 100%	2 100%	2 66.7%	3 75%	1 50%	3 75%	4 80%
Serious AE	1 50%	1 33.3%	1 50%	0 0%	2 50%	1 50%	1 25%	2 40%
AE Leading to any Study Treatment Discontinuation	0 0%	1 33.3%	2 100%	1 33.3%	1 25%	0 0%	2 50%	2 40%
AE Leading to Dose Reductions	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
AE Leading to Dose Interruptions	1 50%	0 0%	0 0%	0 0%	1 25%	0 0%	3 75%	1 20%
AE Leading to Study Discontinuation	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Related to Idasanutlin - Any AE	1 50%	2 66.7%	2 100%	2 66.7%	4 100%	1 50%	4 100%	5 100%
Related to Idasanutlin - Grade 3-5 AE	1 50%	2 66.7%	2 100%	1 33.3%	2 50%	1 50%	3 75%	4 80%
Related to Idasanutlin - Serious AE	1 50%	0 0%	1 50%	0 0%	1 25%	0 0%	0 0%	2 40%
Related to Obinutuzumab - Any AE	1 50%	2 66.7%	2 100%	0 0%	1 25%	0 0%	3 75%	5 100%
Related to Obinutuzumab - Grade 3-5 AE	1 50%	1 33.3%	2 100%	0 0%	0 0%	0 0%	2 50%	3 60%
Related to Obinutuzumab - Serious AE	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	1 25%	1 20%
Related to Rituximab - Any AE	0 0%	0 0%	0 0%	2 66.7%	2 50%	0 0%	0 0%	0 0%
Related to Rituximab - Grade 3-5 AE	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Related to Rituximab - Serious AE	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Related AE Leading to Treatment Discontinuation	0 0%	0 0%	2 100%	1 33.3%	1 25%	0 0%	2 50%	1 20%

16. Secondary Outcome

Title	Baseline Value and Change From Baseline Values of Systolic Blood Pressure at Specified Timepoints
Description	Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Time Frame	Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Baseline (BL) - Value at Visit	176.0 (NA)	124.0 (7.9)	107.5 (2.1)	125.7 (39.4)	119.0 (16.8)	120.5 (17.7)	109.3 (9.1)	116.4 (10.5)
Change from BL at Cycle 1 Day 1	-34.0 (NA)	-2.0 (10.5)	-5.0 (4.2)	-2.7 (14.6)	-0.8 (10.6)	-3.5 (10.6)	3.5 (9.4)	4.8 (14.8)
Change from BL at Cycle 1 Day 8	-4.0 (NA)	-5.0 (8.5)	-7.0 (8.5)	-6.5 (6.4)	-2.3 (15.2)	6.4 (10.3)
Change from BL at Cycle 1 Day 15	24.0 (NA)	-5.3 (14.6)	-3.5 (7.8)	9.7 (13.4)	8.0 (12.9)
Change from BL at Cycle 2 Day 1	-17.0 (NA)	-3.5 (19.1)	0.0 (39.6)	-14.0 (NA)	4.5 (4.9)	8.6 (10.4)
Change from BL at Cycle 3 Day 1	-1.0 (NA)	11.0 (NA)	-13.5 (3.5)	10.5 (2.1)	7.0 (8.9)
Change from BL at Cycle 4 Day 1	-22.0 (NA)	12.5 (27.6)	2.0 (1.4)	-10.0 (NA)
Change from BL at Cycle 5 Day 1	-21.0 (NA)	0.5 (4.9)	12.5 (9.2)	8.5 (9.2)
Change from BL at Cycle 6 Day 1	-2.0 (NA)	20.0 (NA)	0.5 (0.7)
Change from BL at Maint. Month 1	-14.0 (NA)	14.0 (9.9)
Change from BL at Maint. Month 3	9.0 (NA)	7.5 (10.6)
Change from BL at Maint. Month 5	-12.0 (NA)	9.0 (NA)
Change from BL at Maint. Month 7	-5.0 (NA)	0.0 (NA)
Change from BL at Maint. Month 9	-3.0 (NA)	7.0 (NA)
Change from BL at Maint. Month 11	-5.0 (NA)
Change from BL at Maint. Month 13	-5.0 (NA)
Change from BL at Maint. Month 15	-9.0 (NA)
Change from BL at Maint. Month 17	-35.0 (NA)
Change from BL at Maint. Month 19	2.0 (NA)
Change from BL at Maint. Month 21	-21.0 (NA)
Change from BL at Follow-Up	-32.0 (NA)	-3.5 (9.2)	-25.0 (55.2)	-3.5 (0.7)	9.5 (3.5)	20.0 (15.5)	-1.3 (9.0)

17. Secondary Outcome

Title	Baseline Value and Change From Baseline Values of Diastolic Blood Pressure at Specified Timepoints
Description	Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Time Frame	Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Baseline (BL) - Value at Visit	100.0 (NA)	67.3 (12.1)	72.0 (9.9)	72.3 (12.3)	70.3 (7.6)	71.5 (9.2)	76.3 (12.7)	65.8 (6.9)
Change from BL at Cycle 1 Day 1	-17.0 (NA)	-2.0 (19.5)	-2.5 (2.1)	7.3 (23.1)	-2.3 (7.4)	-2.0 (4.2)	3.0 (4.9)	6.4 (2.1)
Change from BL at Cycle 1 Day 8	-1.0 (NA)	1.3 (15.0)	-2.5 (6.4)	-2.0 (0.0)	-6.5 (1.3)	9.2 (8.5)
Change from BL at Cycle 1 Day 15	-1.0 (NA)	3.0 (16.4)	6.0 (4.2)	0.0 (6.6)	2.4 (8.3)
Change from BL at Cycle 2 Day 1	7.0 (NA)	0.0 (17.0)	3.5 (13.4)	0.0 (NA)	-8.0 (2.8)	12.0 (5.1)
Change from BL at Cycle 3 Day 1	3.0 (NA)	3.0 (NA)	-5.5 (6.4)	-1.0 (4.2)	5.3 (5.0)
Change from BL at Cycle 4 Day 1	-4.0 (NA)	3.0 (8.5)	-8.0 (7.1)	7.0 (NA)
Change from BL at Cycle 5 Day 1	-2.0 (NA)	3.5 (0.7)	-2.0 (7.1)	2.5 (4.9)
Change from BL at Cycle 6 Day 1	10.0 (NA)	9.0 (NA)	2.5 (3.5)
Change from BL at Maint. Month 1	0.0 (NA)	2.0 (0.0)
Change from BL at Maint. Month 3	14.0 (NA)	5.0 (8.5)
Change from BL at Maint. Month 5	-7.0 (NA)	-5.0 (NA)
Change from BL at Maint. Month 7	7.0 (NA)	-1.0 (NA)
Change from BL at Maint. Month 9	6.0 (NA)	3.0 (NA)
Change from BL at Maint. Month 11	-13.0 (NA)
Change from BL at Maint. Month 13	1.0 (NA)
Change from BL at Maint. Month 15	9.0 (NA)
Change from BL at Maint. Month 17	-4.0 (NA)
Change from BL at Maint. Month 19	7.0 (NA)
Change from BL at Maint. Month 21	0.0 (NA)
Change from BL at Follow-Up	-16.0 (NA)	-9.0 (21.2)	-15.5 (20.5)	4.0 (4.2)	10.5 (2.1)	7.5 (20.2)	9.3 (3.3)

18. Secondary Outcome

Title	Baseline Value and Change From Baseline Values of Pulse Rate at Specified Timepoints
Description	Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Time Frame	Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Baseline (BL) - Value at Visit	73.0 (NA)	65.7 (1.2)	100.5 (17.7)	81.7 (3.1)	76.0 (10.6)	77.5 (12.0)	79.5 (18.6)	80.2 (9.9)
Change from BL at Cycle 1 Day 1	10.0 (NA)	15.7 (21.5)	-9.0 (8.5)	0.0 (9.8)	8.8 (12.0)	2.5 (14.8)	2.3 (6.4)	9.0 (11.1)
Change from BL at Cycle 1 Day 8	-2.0 (NA)	11.0 (2.0)	-2.0 (1.4)	-0.5 (20.5)	2.3 (6.4)	9.0 (11.1)
Change from BL at Cycle 1 Day 15	-11.0 (NA)	12.7 (13.4)	-3.5 (16.3)	-1.7 (13.1)	3.2 (14.5)
Change from BL at Cycle 2 Day 1	4.0 (NA)	17.5 (17.7)	7.0 (1.4)	-17.0 (NA)	-2.5 (4.9)	6.4 (9.7)
Change from BL at Cycle 3 Day 1	-1.0 (NA)	19.0 (NA)	-1.5 (16.3)	-4.5 (20.5)	-3.5 (10.6)
Change from BL at Cycle 4 Day 1	1.0 (NA)	-7.0 (12.7)	-5.0 (5.7)	4.0 (NA)
Change from BL at Cycle 5 Day 1	15.0 (NA)	-6.5 (10.6)	3.0 (28.3)	6.5 (4.9)
Change from BL at Cycle 6 Day 1	-1.0 (NA)	31.0 (NA)	15.0 (2.8)
Change from BL at Maint. Month 1	6.0 (NA)	10.0 (5.7)
Change from BL at Maint. Month 3	0.0 (NA)	2.0 (9.9)
Change from BL at Maint. Month 5	-5.0 (NA)	11.0 (NA)
Change from BL at Maint. Month 7	1.0 (NA)	2.0 (NA)
Change from BL at Maint. Month 9	6.0 (NA)	11.0 (NA)
Change from BL at Maint. Month 11	18.0 (NA)
Change from BL at Maint. Month 13	11.0 (NA)
Change from BL at Maint. Month 15	2.0 (NA)
Change from BL at Maint. Month 17	-2.0 (NA)
Change from BL at Maint. Month 19	1.0 (NA)
Change from BL at Maint. Month 21	13.0 (NA)
Change from BL at Follow-Up	15.0 (NA)	-20.0 (18.4)	11.5 (10.6)	23.5 (20.5)	15.0 (8.5)	5.8 (14.8)	10.3 (9.2)

19. Secondary Outcome

Title	Baseline Value and Change From Baseline Values of Respiratory Rate at Specified Timepoints
Description	Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Time Frame	Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Baseline (BL) - Value at Visit	18.0 (NA)	17.0 (2.6)	19.0 (1.4)	17.0 (1.7)	17.0 (2.0)	16.0 (0.0)	16.0 (3.3)	16.8 (3.0)
Change from BL at Cycle 1 Day 1	0.0 (NA)	0.7 (1.2)	-1.0 (1.4)	-0.7 (1.2)	0.3 (1.3)	1.0 (1.4)	2.3 (0.5)	0.0 (0.0)
Change from BL at Cycle 1 Day 8	0.0 (NA)	-1.7 (2.1)	-1.0 (1.4)	0.0 (0.0)	2.0 (4.0)	0.0 (2.4)
Change from BL at Cycle 1 Day 15	0.0 (NA)	-3.5 (2.1)	1.0 (1.4)	1.7 (1.5)	-0.2 (2.7)
Change from BL at Cycle 2 Day 1	0.0 (NA)	-2.5 (3.5)	0.5 (0.7)	0.0 (NA)	4.0 (5.7)	0.0 (4.6)
Change from BL at Cycle 3 Day 1	2.0 (NA)	-4.0 (NA)	0.0 (0.0)	4.0 (5.7)	-1.0 (4.2)
Change from BL at Cycle 4 Day 1	-2.0 (NA)	0.0 (0.0)	2.0 (2.8)	4.0 (NA)
Change from BL at Cycle 5 Day 1	0.0 (NA)	0.0 (0.0)	1.0 (1.4)	0.0 (5.7)
Change from BL at Cycle 6 Day 1	-4.0 (NA)	5.0 (NA)	-2.0 (2.8)
Change from BL at Maint. Month 1	-4.0 (NA)	-1.0 (4.2)
Change from BL at Maint. Month 3	0.0 (NA)	-2.0 (2.8)
Change from BL at Maint. Month 5	0.0 (NA)	-4.0 (NA)
Change from BL at Maint. Month 7	0.0 (NA)	-4.0 (NA)
Change from BL at Maint. Month 9	2.0 (NA)	-4.0 (NA)
Change from BL at Maint. Month 11	0.0 (NA)
Change from BL at Maint. Month 13	0.0 (NA)
Change from BL at Maint. Month 15	0.0 (NA)
Change from BL at Maint. Month 17	2.0 (NA)
Change from BL at Maint. Month 19	0.0 (NA)
Change from BL at Maint. Month 21	2.0 (NA)
Change from BL at Follow-Up	-2.0 (NA)	-2.0 (2.8)	-4.0 (NA)	0.0 (2.8)	1.0 (1.4)	3.3 (3.2)	-0.7 (3.1)

20. Secondary Outcome

Title	Baseline Value and Change From Baseline Values of Body Temperature at Specified Timepoints
Description	Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. Maint. = maintenance
Time Frame	Baseline, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2-6 (up to 6 cycles; 1 cycle is 28 days), and then every 2 months (FL) or every month (DLBCL) until end of maintenance or consolidation treatment, respectively (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Baseline (BL) - Value at Visit	36.60 (NA)	36.47 (0.45)	36.35 (0.21)	36.83 (0.15)	36.58 (0.34)	36.55 (0.21)	36.50 (0.18)	36.70 (3.3)
Change from BL at Cycle 1 Day 1	0.00 (NA)	0.00 (0.92)	-0.15 (0.21)	-0.07 (0.15)	0.18 (0.33)	0.05 (0.49)	0.30 (0.22)	-0.18 (0.30)
Change from BL at Cycle 1 Day 8	0.10 (NA)	0.37 (0.50)	0.95 (0.85)	0.30 (0.28)	-0.13 (0.22)	0.10 (0.45)
Change from BL at Cycle 1 Day 15	0.10 (NA)	0.20 (0.82)	0.20 (0.28)	-0.23 (0.45)	-0.18 (0.26)
Change from BL at Cycle 2 Day 1	0.00 (NA)	0.10 (0.14)	-0.30 (0.14)	-0.50 (NA)	-0.25 (0.49)	-0.04 (0.09)
Change from BL at Cycle 3 Day 1	-0.20 (NA)	-0.10 (NA)	-0.10 (0.42)	-0.50 (0.28)	-0.17 (0.21)
Change from BL at Cycle 4 Day 1	0.00 (NA)	0.05 (0.64)	0.05 (0.21)	-0.10 (NA)
Change from BL at Cycle 5 Day 1	0.20 (NA)	0.35 (0.64)	-0.35 (0.49)	-0.20 (0.14)
Change from BL at Cycle 6 Day 1	0.20 (NA)	0.20 (NA)	-0.05 (0.21)
Change from BL at Maint. Month 1	0.60 (NA)	-0.20 (0.14)
Change from BL at Maint. Month 3	0.40 (NA)	-0.20 (0.57)
Change from BL at Maint. Month 5	0.20 (NA)	-0.20 (NA)
Change from BL at Maint. Month 7	0.60 (NA)	-0.10 (NA)
Change from BL at Maint. Month 9	0.30 (NA)	0.20 (NA)
Change from BL at Maint. Month 11	0.70 (NA)
Change from BL at Maint. Month 13	0.40 (NA)
Change from BL at Maint. Month 15	0.70 (NA)
Change from BL at Maint. Month 17	0.40 (NA)
Change from BL at Maint. Month 19	0.80 (NA)
Change from BL at Maint. Month 21	0.50 (NA)
Change from BL at Follow-Up	0.10 (NA)	0.00 (0.14)	-0.40 (0.14)	0.53 (0.71)	0.30 (0.57)	-0.15 (0.47)	-0.10 (0.24)

21. Secondary Outcome

Title	Number of Participants by Electrocardiogram (ECG) Results Assessment Shift From Baseline to Specified Post-Baseline Timepoints
Description	Single, resting, 12-lead ECG recordings were to be obtained after the participant had been resting in a supine position for at least 10 minutes. Any morphologic waveform changes or other ECG abnormalities were to be documented and clinical significance was determined based on the presence of symptoms, per the investigator's judgment. If the ECG assessment was missing at baseline then it was recorded as "Missing". The ECG results assessments are presented as the shift from baseline to post-baseline assessments at each timepoint. BL = baseline; Cyc1, D1 = Induction Cycle 1 Day 1; Cyc4, D1 = Induction Cycle 4 Day 1; CS = Clinically Significant; EOI = End of Induction Treatment - Completion/Discontinuation; EOM = End of Maintenance Treatment - Completion/Discontinuation; MM1 = Maintenance Month 1; Unsched = Unscheduled Visit
Time Frame	Baseline, Induction Cycle 1 Day 1 and Cycle 4 Day 1, End of Induction (up to 6 cycles; 1 cycle is 28 days); Every 2 months during maintenance treatment from Months 1-23; End of Maintenance (up to 24 months); Unscheduled Visits (as clinically indicated)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment. The number analyzed includes participants who were evaluable at each timepoint.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Cyc1, D1: Normal (BL) to Normal	1 50%	1 33.3%	0 0%	2 66.7%	0 0%	4 200%	2 50%
Cyc1, D1: Normal (BL) to Abnormal, not CS	1 50%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%
Cyc1, D1: Abnormal, not CS (BL) to Normal	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	1 25%
Cyc1,D1: Abnormal, not CS (BL) to Abnormal, not CS	1 50%	1 33.3%	1 50%	2 66.7%	1 25%	0 0%	2 50%
Cyc4, D1: Normal (BL) to Normal	0 0%	0 0%	2 100%	1 33.3%
Cyc4, D1: Normal (BL) to Abnormal, not CS	1 50%	0 0%	0 0%	0 0%
Cyc4, D1: Abnormal, not CS (BL) to Normal	0 0%	0 0%	0 0%	1 33.3%
Cyc4,D1: Abnormal, not CS (BL) to Abnormal, not CS	0 0%	1 33.3%	0 0%	0 0%
Cyc4, D1: Missing (BL) to Normal	0 0%	1 33.3%	0 0%	0 0%
EOI: Normal (BL) to Normal	0 0%	0 0%	1 50%	0 0%	2 50%	0 0%	3 75%	2 40%
EOI: Normal (BL) to Abnormal, not CS	1 50%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
EOI: Abnormal, not CS (BL) to Abnormal, not CS	0 0%	1 33.3%	1 50%	1 33.3%	1 25%	1 50%	0 0%	1 20%
EOI: Missing (BL) to Normal	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%
MM1: Normal (BL) to Normal	1 50%
MM1: Abnormal, not CS (BL) to Abnormal, not CS	1 50%
MM3: Abnormal, not CS (BL) to Normal	1 50%
MM5: Abnormal, not CS (BL) to Normal	1 50%
MM7: Missing (BL) to Abnormal, not CS	1 50%
MM9: Missing (BL) to Abnormal, not CS	1 50%
MM11: Missing (BL) to Abnormal, not CS	1 50%
MM13: Missing (BL) to Abnormal, not CS	1 50%
MM15: Missing (BL) to Abnormal, not CS	1 50%
MM17: Missing (BL) to Abnormal, not CS	1 50%
MM19: Missing (BL) to Abnormal, not CS	1 50%
MM21: Missing (BL) to Abnormal, not CS	1 50%
MM23: Missing (BL) to Abnormal, not CS	1 50%
EOM: Normal (BL) to Normal	0 0%	1 33.3%
EOM: Missing (BL) to Abnormal, not CS	1 50%	0 0%
Unsched: Normal (BL) to Normal	1 50%	0 0%	1 50%	0 0%
Unsched: Normal (BL) to Abnormal, not CS	0 0%	0 0%	1 50%	0 0%
Unsched: Abnormal, not CS (BL) to Normal	0 0%	0 0%	0 0%	1 33.3%
Unsched: Abnormal, not CS (BL) to Abnormal, not CS	0 0%	1 33.3%	0 0%	0 0%
Unsched: Abnormal, not CS (BL) to Abnormal, CS	0 0%	0 0%	0 0%	1 33.3%

22. Secondary Outcome

Title	Hematology Laboratory Test Results Shift Table: Number of Participants by Highest NCI-CTCAE v4.0 Grade at Baseline to Highest Grade Post-Baseline
Description	Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest (worst) severity grade (according to NCI-CTCAE v4.0) at baseline to the highest grade post-baseline. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a medical intervention or a change in concomitant therapy. For a patient with multiple post-baseline abnormalities, the highest (worst) grade for a given lab test is reported. Abs. = absolute count; BL = baseline; WBC = white blood cell count
Time Frame	From Baseline until 35 days after the last dose of study drug (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Hemoglobin (g/L), High: Grade (Gr.) 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	4 100%	2 100%	4 100%	5 100%
Hemoglobin (g/L), Low: Gr. 0 (BL) to 0	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	1 20%
Hemoglobin (g/L), Low: Gr. 0 (BL) to 2	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	2 50%	0 0%
Hemoglobin (g/L), Low: Gr. 0 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%
Hemoglobin (g/L), Low: Gr. 1 (BL) to 1	0 0%	2 66.7%	0 0%	2 66.7%	3 75%	0 0%	1 25%	1 20%
Hemoglobin (g/L), Low: Gr. 1 (BL) to 2	0 0%	1 33.3%	1 50%	0 0%	0 0%	0 0%	0 0%	2 40%
Hemoglobin (g/L), Low: Gr. 1 (BL) to 3	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Hemoglobin (g/L), Low: Gr. 2 (BL) to 2	1 50%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Hemoglobin (g/L), Low: Gr. 2 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Hemoglobin (g/L), Low: Gr. 3 (BL) to 3	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	4 100%	2 100%	4 100%	5 100%
Lymphocytes Abs. (10^9/L), Low: Gr. 0 (BL) to 0	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	1 25%	1 20%
Lymphocytes Abs. (10^9/L), Low: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 0 (BL) to 2	1 50%	0 0%	0 0%	1 33.3%	2 50%	0 0%	1 25%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 0 (BL) to 3	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	2 50%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 0 (BL) to 4	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 1 (BL) to 0	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Lymphocytes Abs. (10^9/L), Low: Gr. 1 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 1 (BL) to 3	0 0%	0 0%	1 50%	0 0%	1 25%	0 0%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 2 (BL) to 2	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 2 (BL) to 4	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Lymphocytes Abs. (10^9/L), Low: Gr. 3 (BL) to 2	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 3 (BL) to 3	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	1 20%
Lymphocytes Abs. (10^9/L), Low: Gr. 3 (BL) to 4	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Lymphocytes Abs. (10^9/L), Low: Gr. 4 (BL) to 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Neutrophils,Total Abs (10^9/L),Low: Gr. 0(BL) to 0	0 0%	2 66.7%	0 0%	2 66.7%	2 50%	0 0%	1 25%	2 40%
Neutrophils,Total Abs (10^9/L),Low: Gr. 0(BL) to 1	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Neutrophils,Total Abs (10^9/L),Low: Gr. 0(BL) to 2	0 0%	1 33.3%	0 0%	0 0%	0 0%	1 50%	0 0%	1 20%
Neutrophils,Total Abs (10^9/L),Low: Gr. 0(BL) to 3	1 50%	0 0%	0 0%	1 33.3%	1 25%	0 0%	0 0%	1 20%
Neutrophils,Total Abs (10^9/L),Low: Gr. 0(BL) to 4	0 0%	0 0%	2 100%	0 0%	0 0%	1 50%	2 50%	1 20%
Neutrophils,Total Abs (10^9/L),Low: Gr. 2(BL) to 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%
Platelets (10^9/L), Low: Gr. 0 (BL) to 0	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Platelets (10^9/L), Low: Gr. 0 (BL) to 1	0 0%	1 33.3%	0 0%	1 33.3%	1 25%	1 50%	1 25%	1 20%
Platelets (10^9/L), Low: Gr. 0 (BL) to 2	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Platelets (10^9/L), Low: Gr. 0 (BL) to 3	1 50%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Platelets (10^9/L), Low: Gr. 0 (BL) to 4	0 0%	0 0%	2 100%	1 33.3%	2 50%	1 50%	2 50%	1 20%
Platelets (10^9/L), Low: Gr. 1 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Platelets (10^9/L), Low: Gr. 1 (BL) to 3	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Platelets (10^9/L), Low: Gr. 1 (BL) to 4	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	1 20%
WBC (10^9/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	4 100%	2 100%	4 100%	5 100%
WBC (10^9/L), Low: Gr. 0 (BL) to 0	0 0%	0 0%	0 0%	2 66.7%	2 50%	0 0%	0 0%	1 20%
WBC (10^9/L), Low: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	2 40%
WBC (10^9/L), Low: Gr. 0 (BL) to 2	1 50%	2 66.7%	0 0%	1 33.3%	0 0%	1 50%	1 25%	0 0%
WBC (10^9/L), Low: Gr. 0 (BL) to 3	0 0%	0 0%	2 100%	0 0%	1 25%	0 0%	1 25%	0 0%
WBC (10^9/L), Low: Gr. 0 (BL) to 4	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	1 20%
WBC (10^9/L), Low: Gr. 1 (BL) to 0	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
WBC (10^9/L), Low: Gr. 1 (BL) to 1	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
WBC (10^9/L), Low: Gr. 1 (BL) to 2	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
WBC (10^9/L), Low: Gr. 1 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%

23. Secondary Outcome

Title	Blood Chemistry Laboratory Test Results Shift Table: Number of Participants by Highest NCI-CTCAE v4.0 Grade at Baseline to Highest Grade Post-Baseline
Description	Clinical laboratory tests for blood chemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest (worst) severity grade (according to NCI-CTCAE v4.0) at baseline to the highest grade post-baseline. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a medical intervention or a change in concomitant therapy. For a patient with multiple post-baseline abnormalities, the highest (worst) grade for a given lab test is reported. BL = Baseline; Blood Gluc., Fast. = blood glucose, fasting; SGOT/AST = serum glutamic-oxaloacetic transaminase/aspartate transaminase; SGPT/ALT = serum glutamic-pyruvic transaminase/alanine transaminase; Triacylglyc. Lipase = triacylglycerol lipase
Time Frame	From Baseline until 35 days after the last dose of study drug (up to 29 months)

Outcome Measure Data

Analysis Population Description
Safety Population: participants who received at least one dose of any component of the combination treatment.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg	DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2	DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2	FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg	FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg	FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).	Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
Measure Participants	1	3	2	3	4	2	4	5
Albumin (g/L), Low: Grade (Gr.) 0 (BL) to 0	1 50%	3 100%	2 100%	1 33.3%	2 50%	2 100%	4 100%	3 60%
Albumin (g/L), Low: Grade (Gr.) 0 (BL) to 1	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Albumin (g/L), Low: Grade (Gr.) 0 (BL) to 2	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	1 20%
Albumin (g/L), Low: Grade (Gr.) 1 (BL) to 1	0 0%	0 0%	0 0%	1 33.3%	1 25%	0 0%	0 0%	1 20%
Alkaline Phosphatase (U/L), High: Gr. 0 (BL) to 0	0 0%	3 100%	2 100%	2 66.7%	3 75%	1 50%	4 100%	3 60%
Alkaline Phosphatase (U/L), High: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	0 0%	1 25%	1 50%	0 0%	1 20%
Alkaline Phosphatase (U/L), High: Gr. 1 (BL) to 1	1 50%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	1 20%
Amylase (U/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	1 25%	2 100%	3 75%	5 100%
Amylase (U/L), High: Missing (BL) to Gr. 0	0 0%	0 0%	0 0%	0 0%	2 50%	0 0%	1 25%	0 0%
Amylase (U/L), High: Gr. 1 (BL) to 1	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Bilirubin (umol/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	4 100%	2 100%	3 75%	5 100%
Bilirubin (umol/L), High: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%
Blood Gluc,Fast(mmol/L), High: Missing(BL) to Gr 0	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	1 25%	1 20%
Blood Gluc,Fast(mmol/L), High: Gr. 0(BL) to 1	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Blood Gluc,Fast(mmol/L), High: Gr. 1 (BL) to 1	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Blood Gluc,Fast(mmol/L), High: Missing(BL) to Gr 2	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Blood Gluc.,Fast.(mmol/L), High: Missing (All)	0 0%	3 100%	0 0%	3 100%	4 100%	1 50%	3 75%	4 80%
Blood Gluc,Fast(mmol/L), Low: Gr. 0 (BL) to 0	0 0%	0 0%	2 100%	0 0%	0 0%	0 0%	0 0%	0 0%
Blood Gluc,Fast(mmol/L), Low: Missing(BL) to Gr 0	1 50%	0 0%	0 0%	0 0%	0 0%	1 50%	1 25%	1 20%
Blood Gluc.,Fast.(mmol/L), Low: Missing (All)	0 0%	3 100%	0 0%	3 100%	4 100%	1 50%	3 75%	4 80%
Calcium (mmol/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	3 75%	2 100%	4 100%	5 100%
Calcium (mmol/L), High: Gr. 1 (BL) to 0	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Calcium (mmol/L), Low: Gr. 0 (BL) to 0	1 50%	2 66.7%	2 100%	2 66.7%	3 75%	2 100%	3 75%	4 80%
Calcium (mmol/L), Low: Gr. 0 (BL) to 1	0 0%	1 33.3%	0 0%	0 0%	1 25%	0 0%	1 25%	0 0%
Calcium (mmol/L), Low: Gr. 0 (BL) to 2	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Calcium (mmol/L), Low: Gr. 1 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Creatinine (umol/L), High: Gr. 0 (BL) to 0	0 0%	2 66.7%	0 0%	1 33.3%	0 0%	0 0%	2 50%	3 60%
Creatinine (umol/L), High: Gr. 0 (BL) to 1	0 0%	1 33.3%	2 100%	2 66.7%	2 50%	2 100%	1 25%	1 20%
Creatinine (umol/L), High: Gr. 0 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Creatinine (umol/L), High: Gr. 1 (BL) to 0	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Creatinine (umol/L), High: Gr. 1 (BL) to 1	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%
Creatinine (umol/L), High: Gr. 1 (BL) to 2	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Glucose (mmol/L), High: Gr. 0 (BL) to 0	0 0%	3 100%	0 0%	3 100%	4 100%	2 100%	4 100%	5 100%
Glucose (mmol/L), High: Missing (BL) to Gr. 0	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Glucose (mmol/L), High: Gr. 0 (BL) to 3	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Glucose (mmol/L), High: Missing (All)	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Glucose (mmol/L), Low: Gr. 0 (BL) to 0	1 50%	2 66.7%	0 0%	2 66.7%	4 100%	2 100%	4 100%	4 80%
Glucose (mmol/L), Low: Missing (BL) to Gr. 0	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Glucose (mmol/L), Low: Gr. 0 (BL) to 1	0 0%	1 33.3%	0 0%	1 33.3%	0 0%	0 0%	0 0%	1 20%
Glucose (mmol/L), Low: Missing (All)	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
Phosphorus (mmol/L), Low: Gr. 0 (BL) to 0	0 0%	2 66.7%	2 100%	1 33.3%	2 50%	0 0%	0 0%	2 40%
Phosphorus (mmol/L), Low: Missing (BL) to Gr. 0	1 50%	1 33.3%	0 0%	1 33.3%	0 0%	0 0%	2 50%	1 20%
Phosphorus (mmol/L), Low: Missing (BL) to Gr. 2	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Phosphorus (mmol/L), Low: Missing (All)	0 0%	0 0%	0 0%	1 33.3%	1 25%	1 50%	2 50%	2 40%
Potassium (mmol/L), High: Gr. 0 (BL) to 0	0 0%	3 100%	2 100%	2 66.7%	4 100%	2 100%	4 100%	5 100%
Potassium (mmol/L), High: Gr. 0 (BL) to 1	1 50%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Potassium (mmol/L), Low: Gr. 0 (BL) to 0	1 50%	2 66.7%	2 100%	3 100%	3 75%	2 100%	4 100%	3 60%
Potassium (mmol/L), Low: Gr. 0 (BL) to 2	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Potassium (mmol/L), Low: Gr. 2 (BL) to 0	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Potassium (mmol/L), Low: Gr. 2 (BL) to 2	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 40%
SGOT/AST (U/L), High: Gr. 0 (BL) to 0	1 50%	2 66.7%	2 100%	2 66.7%	4 100%	2 100%	4 100%	5 100%
SGOT/AST (U/L), High: Gr. 1 (BL) to 0	0 0%	1 33.3%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
SGPT/ALT (U/L), High: Gr. 0 (BL) to 0	1 50%	2 66.7%	1 50%	3 100%	2 50%	2 100%	4 100%	5 100%
SGPT/ALT (U/L), High: Gr. 1 (BL) to 0	0 0%	1 33.3%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%
SGPT/ALT (U/L), High: Gr. 1 (BL) to 1	0 0%	0 0%	0 0%	0 0%	2 50%	0 0%	0 0%	0 0%
Sodium (mmol/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	3 75%	2 100%	4 100%	4 80%
Sodium (mmol/L), High: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Sodium (mmol/L), High: Gr. 1 (BL) to 0	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Sodium (mmol/L), Low: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	2 66.7%	4 100%	2 100%	4 100%	3 60%
Sodium (mmol/L), Low: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	1 33.3%	0 0%	0 0%	0 0%	0 0%
Sodium (mmol/L), Low: Gr. 0 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Sodium (mmol/L), Low: Gr. 1 (BL) to 0	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Triacylglyc. Lipase (U/L), High: Gr. 0 (BL) to 0	0 0%	3 100%	2 100%	3 100%	2 50%	1 50%	3 75%	4 80%
Triacylglyc. Lipase (U/L), High: Gr. 0 (BL) to 1	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%
Triacylglyc. Lipase (U/L), High: Gr. 0 (BL) to 3	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Triacylglyc Lipase (U/L),High: Missing(BL) to Gr 0	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	1 20%
Triacylglyc Lipase (U/L),High: Missing(BL) to Gr 2	0 0%	0 0%	0 0%	0 0%	2 50%	0 0%	0 0%	0 0%
Uric Acid (umol/L), High: Gr. 0 (BL) to 0	1 50%	3 100%	2 100%	3 100%	2 50%	2 100%	3 75%	4 80%
Uric Acid (umol/L), High: Missing(BL) to Gr. 0	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%
Uric Acid (umol/L), High: Gr. 0 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 20%
Uric Acid (umol/L), High: Gr. 3 (BL) to 3	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%
Uric Acid (umol/L), High: Gr. 4 (BL) to 3	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%

Adverse Events

	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg		DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2		DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2		FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Time Frame	From first dose until 90 days after the last dose of study drug treatment (up to 31 months), except for serious AEs related to treatment
Adverse Event Reporting Description	Investigators seek information on adverse events (AEs) at each patient contact. All AEs were recorded, regardless of who reported them. After informed consent but prior to initiation of study drug, only serious AEs caused by protocol-mandated intervention were to be reported. After initiation of study drug, all AEs were to be reported until 90 days after the last dose of study drug. After this period, only serious AEs believed to be related to prior study drug treatment were to be reported.

Arm/Group Title	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg		DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2		DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2		FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
Arm/Group Description	Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).		Participants with relapsed/refractory follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
All Cause Mortality
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/1 (0%)		1/3 (33.3%)		2/2 (100%)		2/3 (66.7%)		2/4 (50%)		0/2 (0%)		0/4 (0%)		1/5 (20%)
Serious Adverse Events
	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg		DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2		DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2		FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/1 (100%)		1/3 (33.3%)		1/2 (50%)		0/3 (0%)		2/4 (50%)		1/2 (50%)		1/4 (25%)		2/5 (40%)
Blood and lymphatic system disorders
Febrile neutropenia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Pancytopenia	0/1 (0%)	0	0/3 (0%)	0	1/2 (50%)	1	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Cardiac disorders
Acute myocardial infarction	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Gastrointestinal disorders
Ascites	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Diarrhoea	1/1 (100%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
General disorders
Peripheral swelling	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Infections and infestations
Gastroenteritis	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Pneumonia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Injury, poisoning and procedural complications
Infusion related reaction	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	1/4 (25%)	1	0/5 (0%)	0
Renal and urinary disorders
Acute kidney injury	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Other (Not Including Serious) Adverse Events
	DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg		DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2		DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2		FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg		FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg		FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/1 (100%)		3/3 (100%)		2/2 (100%)		3/3 (100%)		4/4 (100%)		2/2 (100%)		4/4 (100%)		5/5 (100%)
Blood and lymphatic system disorders
Anaemia	0/1 (0%)	0	0/3 (0%)	0	2/2 (100%)	2	1/3 (33.3%)	1	0/4 (0%)	0	1/2 (50%)	2	3/4 (75%)	3	2/5 (40%)	3
Leukopenia	0/1 (0%)	0	2/3 (66.7%)	3	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	1/4 (25%)	2	1/5 (20%)	1
Lymphopenia	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	1/3 (33.3%)	2	0/4 (0%)	0	0/2 (0%)	0	1/4 (25%)	1	1/5 (20%)	1
Neutropenia	1/1 (100%)	1	0/3 (0%)	0	2/2 (100%)	3	1/3 (33.3%)	2	4/4 (100%)	4	1/2 (50%)	2	3/4 (75%)	10	3/5 (60%)	4
Thrombocytopenia	1/1 (100%)	1	2/3 (66.7%)	2	2/2 (100%)	2	1/3 (33.3%)	2	2/4 (50%)	2	2/2 (100%)	2	4/4 (100%)	7	4/5 (80%)	6
Cardiac disorders
Atrial fibrillation	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Tachycardia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	3	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Gastrointestinal disorders
Diarrhoea	0/1 (0%)	0	1/3 (33.3%)	1	1/2 (50%)	2	2/3 (66.7%)	3	0/4 (0%)	0	1/2 (50%)	4	3/4 (75%)	8	3/5 (60%)	5
Nausea	1/1 (100%)	2	1/3 (33.3%)	1	1/2 (50%)	1	2/3 (66.7%)	2	0/4 (0%)	0	2/2 (100%)	6	3/4 (75%)	8	5/5 (100%)	11
Constipation	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/2 (50%)	1	0/4 (0%)	0	2/5 (40%)	3
Gastrointestinal pain	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	2/4 (50%)	3	0/5 (0%)	0
Abdominal pain	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Anal inflammation	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Dry mouth	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Dyspepsia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Flatulence	1/1 (100%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Stomatitis	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Vomiting	0/1 (0%)	0	1/3 (33.3%)	1	1/2 (50%)	1	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	3/5 (60%)	4
General disorders
Chest pain	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Fatigue	1/1 (100%)	1	1/3 (33.3%)	1	1/2 (50%)	1	1/3 (33.3%)	1	0/4 (0%)	0	1/2 (50%)	1	3/4 (75%)	8	1/5 (20%)	1
Oedema	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Oedema peripheral	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Pain	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Pyrexia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	2/4 (50%)	3	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Infections and infestations
Clostridium difficile infection	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	2	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Upper respiratory tract infection	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	1/4 (25%)	1	0/5 (0%)	0
Herpes zoster	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	1/4 (25%)	1	0/5 (0%)	0
Skin infection	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Chronic sinusitis	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Nasopharyngitis	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	2/4 (50%)	2	0/5 (0%)	0
Sinusitis	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	1/4 (25%)	1	1/5 (20%)	1
Injury, poisoning and procedural complications
Infusion related reaction	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	1/4 (25%)	1	1/5 (20%)	1
Investigations
Blood albumin decreased	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Blood bilirubin increased	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	1/4 (25%)	1	0/5 (0%)	0
Blood lactate dehydrogenase increased	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Haemophilus test positive	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Lipase increased	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Metabolism and nutrition disorders
Decreased appetite	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	1/4 (25%)	1	1/5 (20%)	1
Dehydration	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Hypokalaemia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	1/4 (25%)	1	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Hypomagnesaemia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Hypophosphataemia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Musculoskeletal and connective tissue disorders
Muscle spasms	1/1 (100%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Musculoskeletal chest pain	1/1 (100%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Arthritis	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Groin pain	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Myalgia	0/1 (0%)	0	0/3 (0%)	0	1/2 (50%)	1	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Pain in extremity	1/1 (100%)	1	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Nervous system disorders
Dizziness	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	2/3 (66.7%)	2	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Dysgeusia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Headache	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1
Memory impairment	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Taste disorder	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	1/4 (25%)	1	0/5 (0%)	0
Trigeminal neuralgia	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Psychiatric disorders
Depression	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Respiratory, thoracic and mediastinal disorders
Cough	1/1 (100%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	2/5 (40%)	2
Dyspnoea exertional	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Nasal congestion	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	1/5 (20%)	1
Rhinitis allergic	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Skin and subcutaneous tissue disorders
Eczema	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	1/2 (50%)	1	0/4 (0%)	0	0/5 (0%)	0
Night sweats	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Skin ulcer	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Vascular disorders
Deep vein thrombosis	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	1/3 (33.3%)	1	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Hot flush	0/1 (0%)	0	1/3 (33.3%)	1	0/2 (0%)	0	0/3 (0%)	0	0/4 (0%)	0	0/2 (0%)	0	0/4 (0%)	0	0/5 (0%)	0
Hypotension	0/1 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0	1/4 (25%)	1	0/2 (0%)	0	0/4 (0%)	0	1/5 (20%)	1

Limitations/Caveats

Due to the overall modest benefit achieved with the maximum tolerated dose during the dose escalation phase, the Sponsor decided not to open the expansion phase and terminated the study. Consequently, some planned analyses could not be performed.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact

Name/Title	Medical Communications
Organization	Hoffmann-La Roche
Phone	800-821-8590
Email	genentech@druginfo.com

Responsible Party:

Hoffmann-La Roche

ClinicalTrials.gov Identifier:

NCT02624986

Other Study ID Numbers:

BH29812
2015-002100-83

First Posted:

Dec 9, 2015

Last Update Posted:

May 18, 2020

Last Verified:

Apr 1, 2020

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Study Details

Study Description

Brief Summary

Study Design

Arms and Interventions

Outcome Measures

Primary Outcome Measures

Secondary Outcome Measures

Eligibility Criteria

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Locations

Sponsors and Collaborators

Investigators

Study Documents (Full-Text)

More Information

Publications

Study Results

Participant Flow

Baseline Characteristics

Outcome Measures

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Outcome Measure Data

Adverse Events

All Cause Mortality

Serious Adverse Events

Other (Not Including Serious) Adverse Events

Limitations/Caveats

More Information

Certain Agreements

Results Point of Contact